Northern California

San Francisco-Based Biotech Company to Close, Liquidate Assets

Third Harmonic Bio, once worth $1 billion, has been developing a treatment for chronic spontaneous urticaria, or hives.
San Francisco-Based Biotech Company to Close, Liquidate Assets
A view of San Francisco on June 13, 2018. Justin Sullivan/Getty Images
Jill McLaughlin
|Updated:
0:00
San Francisco-based biopharmaceutical company Third Harmonic Bio has decided to shut down operations and liquidate assets, the company announced April 14.

Third Harmonic Bio, which began operating in 2019, is a clinical-stage biotech operation focused on treating dermal, respiratory, and gastrointestinal inflammatory diseases. It was once worth about $1 billion.

Jill McLaughlin
Jill McLaughlin
Author
Jill McLaughlin is an award-winning journalist covering politics, environment, and statewide issues. She has been a reporter and editor for newspapers in Oregon, Nevada, and New Mexico. Jill was born in Yosemite National Park and enjoys the majestic outdoors, traveling, golfing, and hiking.